Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.

Verreault M, Wehbe M, Strutt D, Masin D, Anantha M, Walker D, Chu F, Backstrom I, Kalra J, Waterhouse D, Yapp DT, Bally MB.

J Control Release. 2015 Dec 28;220(Pt A):348-357. doi: 10.1016/j.jconrel.2015.10.053. Epub 2015 Nov 1.

PMID:
26528901
2.

Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.

Waterhouse DN, Sutherland BW, Santos ND, Masin D, Osooly M, Strutt D, Ostlund C, Anantha M, Harasym N, Manisali I, Wehbe M, Bally MB, Webb MS.

Invest New Drugs. 2014 Dec;32(6):1071-82. doi: 10.1007/s10637-014-0138-x. Epub 2014 Jul 27.

3.

Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model.

Verreault M, Weppler SA, Stegeman A, Warburton C, Strutt D, Masin D, Bally MB.

PLoS One. 2013;8(3):e59597. doi: 10.1371/journal.pone.0059597. Epub 2013 Mar 15.

4.

Characterization of long-circulating cationic nanoparticle formulations consisting of a two-stage PEGylation step for the delivery of siRNA in a breast cancer tumor model.

Ho EA, Osooly M, Strutt D, Masin D, Yang Y, Yan H, Bally M.

J Pharm Sci. 2013 Jan;102(1):227-36. doi: 10.1002/jps.23351. Epub 2012 Nov 6.

PMID:
23132529
5.

Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.

Verreault M, Strutt D, Masin D, Anantha M, Waterhouse D, Yapp DT, Bally MB.

J Control Release. 2012 Feb 28;158(1):34-43. doi: 10.1016/j.jconrel.2011.09.095. Epub 2011 Oct 5.

PMID:
22001870
6.

The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.

Dragowska WH, Weppler SA, Qadir MA, Wong LY, Franssen Y, Baker JH, Kapanen AI, Kierkels GJ, Masin D, Minchinton AI, Gelmon KA, Bally MB.

BMC Cancer. 2011 Oct 1;11:420. doi: 10.1186/1471-2407-11-420.

7.

Development of glioblastoma cell lines expressing red fluorescence for non-invasive live imaging of intracranial tumors.

Verreault M, Strutt D, Masin D, Fink D, Gill R, Bally MB.

Anticancer Res. 2011 Jun;31(6):2161-71.

PMID:
21737636
8.

Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.

Verreault M, Strutt D, Masin D, Anantha M, Yung A, Kozlowski P, Waterhouse D, Bally MB, Yapp DT.

BMC Cancer. 2011 Apr 8;11:124. doi: 10.1186/1471-2407-11-124.

10.

Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles.

Zhigaltsev IV, Winters G, Srinivasulu M, Crawford J, Wong M, Amankwa L, Waterhouse D, Masin D, Webb M, Harasym N, Heller L, Bally MB, Ciufolini MA, Cullis PR, Maurer N.

J Control Release. 2010 Jun 15;144(3):332-40. doi: 10.1016/j.jconrel.2010.02.029. Epub 2010 Mar 2.

PMID:
20202473
11.

Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels.

Tucker CA, Kapanen AI, Chikh G, Hoffman BG, Kyle AH, Wilson IM, Masin D, Gascoyne RD, Bally M, Klasa RJ.

Mol Cancer Ther. 2008 Apr;7(4):749-58. doi: 10.1158/1535-7163.MCT-07-0302. Epub 2008 Mar 28.

12.

Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma.

Tucker CA, Bebb G, Klasa RJ, Chhanabhai M, Lestou V, Horsman DE, Gascoyne RD, Wiestner A, Masin D, Bally M, Williams ME.

Leuk Res. 2006 Apr;30(4):449-57. Epub 2005 Sep 23.

PMID:
16183118
13.

Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity.

Dos Santos N, Waterhouse D, Masin D, Tardi PG, Karlsson G, Edwards K, Bally MB.

J Control Release. 2005 Jun 20;105(1-2):89-105.

PMID:
15878792
14.

HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.

Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB.

Mol Cancer Res. 2004 Nov;2(11):606-19.

16.
17.
18.
19.

Kupffer cells do not play a role in governing the efficacy of liposomal mitoxantrone used to treat a tumor model designed to assess drug delivery to liver.

Lim HJ, Parr MJ, Masin D, McIntosh NL, Madden TD, Zhang G, Johnstone S, Bally MB.

Clin Cancer Res. 2000 Nov;6(11):4449-60.

20.

Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models.

Tardi P, Choice E, Masin D, Redelmeier T, Bally M, Madden TD.

Cancer Res. 2000 Jul 1;60(13):3389-93.

21.
22.

Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone.

Lim HJ, Masin D, Madden TD, Bally MB.

J Pharmacol Exp Ther. 1997 Apr;281(1):566-73.

PMID:
9103545
25.

Liposomal cyclosporine. Comparison of drug and lipid carrier pharmacokinetics and biodistribution.

Choice E, Masin D, Bally MB, Meloche M, Madden TD.

Transplantation. 1995 Nov 15;60(9):1006-11.

PMID:
7491673
27.

Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours.

Mayer LD, Masin D, Nayar R, Boman NL, Bally MB.

Br J Cancer. 1995 Mar;71(3):482-8.

28.

Polyethylene glycol modified phospholipids stabilize emulsions prepared from triacylglycerol.

Wheeler JJ, Wong KF, Ansell SM, Masin D, Bally MB.

J Pharm Sci. 1994 Nov;83(11):1558-64.

PMID:
7891274
29.
30.

Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice.

Bally MB, Masin D, Nayar R, Cullis PR, Mayer LD.

Cancer Chemother Pharmacol. 1994;34(2):137-46.

PMID:
8194164
31.

Liposomes with entrapped doxorubicin exhibit extended blood residence times.

Bally MB, Nayar R, Masin D, Hope MJ, Cullis PR, Mayer LD.

Biochim Biophys Acta. 1990 Mar 30;1023(1):133-9.

PMID:
2317492
32.
33.

Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes.

Bally MB, Nayar R, Masin D, Cullis PR, Mayer LD.

Cancer Chemother Pharmacol. 1990;27(1):13-9.

PMID:
2245488
34.

Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.

Mayer LD, Tai LC, Ko DS, Masin D, Ginsberg RS, Cullis PR, Bally MB.

Cancer Res. 1989 Nov 1;49(21):5922-30.

35.

[Contribution to the differential diagnosis of hypothyroid edema].

HRISOHO D, MASIN D.

Med Glas. 1961 Jul-Aug;15:315-6. Undetermined Language. No abstract available.

PMID:
14449483

Supplemental Content

Support Center